Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer (MCRC) patients

被引：0
|
作者：
Samalin, E.
Lievre, A.
Boyer-Gestin, C.
Mitry, E.
Senesse, P.
Lepere, C.
Bachet, J.
Vaillant, J.
Rougier, J.
Ychou, M.
机构：
[1] Ccentre Aurelle, Montpellier, France
[2] Hop Ambroise Pare, Boulogne Billancourt, France
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII30 / VII30
页数：1
相关论文
共 50 条
  • [41] Genetic variants of Pint to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Zhang, Wu
    Yang, Dongyun
    Berger, Martin D.
    West, Jordan David
    Cremolini, Chiara
    Lonardi, Sara
    Battaglin, Francesca
    Ning, Yan
    Horiike, Yuki
    Yamamoto, Noriko
    Okazaki, Satoshi
    Miyamoto, Yuji
    Hanna, Diana L.
    Barzi, Afsaneh
    Loupakis, Fotios
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [43] CHRONOCHEMOTHERAPY (CCT) WITH FLUOROURACIL, OXALIPLATIN, FOLINIC ACID, IRINOTECAN (FOLFOXIRI) +/-BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC): A PHASE 2 TRIAL
    Lo Re, G.
    Tumolo, S.
    Marzano, B.
    Fanti, G.
    Scata, A.
    Chiara, G.
    Tosolini, G.
    Marus, W.
    Sulfaro, S.
    Santeufemia, D.
    Donadon, V
    Casarin, P.
    Balbi, M.
    Spaziante, R.
    Mancinelli, P.
    ANNALS OF ONCOLOGY, 2009, 20 : 33 - 33
  • [44] Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis
    Kang, Byung Woog
    Kim, Tae Won
    Lee, Jae-Lyun
    Ryu, Min-Hee
    Chang, Heung Moon
    Yu, Chang Sik
    Kim, Jin Cheon
    Kim, Jong Hoon
    Kang, Yoon-Koo
    Lee, Jung Shin
    MEDICAL ONCOLOGY, 2009, 26 (01) : 32 - 37
  • [45] Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis
    Byung Woog Kang
    Tae Won Kim
    Jae-Lyun Lee
    Min-Hee Ryu
    Heung Moon Chang
    Chang Sik Yu
    Jin Cheon Kim
    Jong Hoon Kim
    Yoon-Koo Kang
    Jung Shin Lee
    Medical Oncology, 2009, 26 : 32 - 37
  • [46] Combination Chemotherapy With Capecitabine (C), Irinotecan (I) Oxaliplatin (O) and Bevacizumab (B) (XELOXIRIA) as First Line Treatment of Metastatic Colorectal Cancer (MCRC) - Preliminary Results of a Phase I-II Trial
    Bazarbashi, S.
    Aljubran, A.
    Soudy, H.
    Alzahrani, A.
    Darwish, A.
    Eltaigani, A.
    Nabil-Ahmed, M.
    Edesa, W.
    Shoukri, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S425 - S425
  • [47] Rechallenge of oxaliplatin-containing regimens in the third- or later-line therapy for patients with heavily treated metastatic colorectal cancer
    Yan, Qiong
    Huang, Yuanyuan
    Jian, Zhimin
    Wang, Huizhong
    Li, Weiyu
    Zhang, Bei
    Xie, Derong
    ONCOTARGETS AND THERAPY, 2018, 11 : 2467 - 2473
  • [48] FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer
    Carola, Candice
    Ghiringhelli, Francois
    Kim, Stefano
    Andre, Thierry
    Barlet, Juliette
    Bengrine, Leila
    Marijon, Helene
    Garcia, Marie Line
    Borg, Christophe
    Dainese, Linda
    Steuer, Nils
    Larsen, Annette K.
    De Gramont, Aimery
    Chibaudel, Benoist
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Coi regimen (capecitabine, oxaliplatin, irinotecan) as front-line combination in metastatic colorectal cancer patients (PTS)
    Ferrario, E.
    Di Bartolomeo, M.
    Buzzoni, R.
    Del Vecchio, M.
    Beretta, E.
    Di Marco, R.
    Paleari, D.
    Gevorgyan, A.
    Bajetta, E.
    ANNALS OF ONCOLOGY, 2005, 16 : 41 - 41
  • [50] Combination of capecitabine and oxaliplatine as 2nd line treatment in patients with advanced colorectal cancer
    Heras, P.
    Hatzopoulos, A.
    Karagiannis, S.
    Kritikos, K.
    ANNALS OF ONCOLOGY, 2007, 18 : VII76 - VII76
12345